Silence Therapeutics plc has closed its previously announced public offering, generating approximately $201.3 million in gross proceeds.
Public offerings of this scale provide biotechnology and pharmaceutical companies with critical capital to advance clinical pipelines, fund research and development, and support general corporate operations. Details regarding the specific allocation of the proceeds and the exact share pricing were not immediately elaborated in the initial market announcement.
